Membranski glomerulonefritis--novosti u patogenezi i liječenju [Membranous glomerulonephritis--recent advances in pathogenesis and treatment]

Horvatić, Ivica and Galešić, Krešimir (2012) Membranski glomerulonefritis--novosti u patogenezi i liječenju [Membranous glomerulonephritis--recent advances in pathogenesis and treatment]. Liječnički vjesnik, 134 (11-12). pp. 328-39. ISSN 0024-3477

[img]
Preview
PDF
Download (1MB) | Preview

Abstract

Membranous glomerulonephritis is one of the leading causes of nephrotic syndrome in adults. It may have very variable course, with some patients slowly progressing to renal failure and some entering spontaneous remission. The aim of this article is to review recent advances in the pathogenesis and treatment of the disease in recent years. In recent years, first human podocyte autoantigens, responsible for autoantibodies and in situ immune complexes formation, were discovered: neutral endopeptidase, m-type phospholipase A2 receptor, superoxide-dismutase 2, aldose-reductase, alpha-enolase. It is postulated that these discoveries will help in differentiation between primary and secondary membranous glomerulonephritis, in predicting remission and/or relapse and also in determining more specific therapy. There have been also some pilot studies recently, in which new drugs have been introduced in the treatment of membranous glomerulonephritis: ACTH, rituximab and tacrolimus.

Abstract in Croatian

Membranski glomerulonefritis jedan je od najčešćih uzroka nefrotskog sindroma u odraslih osoba. Obilježen je varijabilnim kliničkim tijekom, u kojem se u nekih bolesnika sporo razvija zatajenje bubrega, dok drugi ulaze u spontanu remisiju. Cilj je ovoga preglednog članka osvrt na novosti koje su posljednjih godina nađene u patogenezi i liječenju ove bolesti u ljudi. Posljednjih godina otkriveni su ciljni podocitni autoantigeni koji su odgovorni za stvaranje autoprotutijela i imunih kompleksa in situ: neutralna endopeptidaza, M-tip receptora za fosfolipazu A2, superoksid-dismutaza 2, aldoza-reduktaza i a-enolaza. Pretpostavlja se da će otkrića ovih antigena pomoći u razlikovanju primarnog od sekundarnoga membranskoga glomerulonefritisa, predviđanju remisije i/ili relapsa bolesti, kao i specifičnijem liječenju bolesti. Posljednjih godina u liječenju bolesti provedene su pilot-studije u kojima su prvi put pokazani pozitivni terapijski učinci ACTH, rituksimaba i takrolimusa.

Item Type: Article
MeSH: Glomerulonephritis, Membranous/physiopathology ; Glomerulonephritis, Membranous/therapy ; Humans
Departments: Katedra za internu medicinu
Depositing User: Marijan Šember
Status: Published
Creators:
CreatorsEmail
Horvatić, IvicaUNSPECIFIED
Galešić, KrešimirUNSPECIFIED
Date: November 2012
Date Deposited: 13 Mar 2014 12:47
Last Modified: 01 Oct 2019 13:45
Subjects: /
Related URLs:
URI: http://medlib.mef.hr/id/eprint/2071

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year